Response to: ‘Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years’ by Yamamoto et al

Published on Aug 1, 2015in Annals of the Rheumatic Diseases16.102
· DOI :10.1136/ANNRHEUMDIS-2015-207640
John H. Stone76
Estimated H-index: 76
(Harvard University),
Mollie N. Carruthers15
Estimated H-index: 15
(Harvard University)
+ 7 AuthorsSuresh T. Chari83
Estimated H-index: 83
(Mayo Clinic)
Sources
Abstract
We thank Yamamoto and colleagues1 for their response to our paper2 and their description of their experience with rituximab (RTX) in IgG4-related disease (IgG4-RD) in three patients. Their letter raises a number of important points pertaining to the management of IgG4-RD, in general, and to the use of B-cell-depletion strategies, specifically. First, their patients are exemplary of the fact a sizeable subset of IgG4-RD patients has a propensity to disease relapse over time. This point has been underappreciated from early reports of the use of glucocorticoids to treat IgG4-RD because those reports were characterised by short follow-up periods. Although the great majority of patients respond to glucocorticoids initially, repeated disease flares are the rule for many. Second, patients with IgG4-RD endure substantial morbidity from the requirement for repeated courses (or continuous on treatment) with glucocorticoids. The three patients described by Yamamoto and colleagues are reported to have experienced bilateral avascular necrosis of the hips and glucose intolerance (severe diabetes mellitus in one case). Our general sense is that the toxicities of prolonged glucocorticoid use in this and other diseases are underestimated. Moreover, patients …
Download
📖 Papers frequently viewed together
29 Citations
2 Citations
References8
Newest
#1Arezou Khosroshahi (Emory University)H-Index: 30
#2Zachary S. Wallace (Harvard University)H-Index: 25
Last. John H. Stone (Harvard University)H-Index: 76
view all 42 authors...
A. Khosroshahi, Z. S. Wallace, J. L. Crowe, T. Akamizu, A. Azumi, M. N. Carruthers, S. T. Chari, E. Della-Torre, L. Frulloni, H. Goto, P. A. Hart, T. Kamisawa, S. Kawa, M. Kawano, M. H. Kim, Y. Kodama, K. Kubota, M. M. Lerch, M. L€ ohr, Y. Masaki, S. Matsui, T. Mimori, S. Nakamura, T. Nakazawa, H. Ohara, K. Okazaki, J. H. Ryu, T. Saeki, N. Schleinitz, A. Shimatsu, T. Shimosegawa, H. Takahashi, M. Takahira, A. Tanaka, M. Topazian, H. Umehara, G. J. Webster, T. E. Witzig, M. Yamamoto, W. Zhang, T....
445 CitationsSource
#1Mollie N. Carruthers (Harvard University)H-Index: 15
#2Mark Topazian (Mayo Clinic)H-Index: 53
Last. John H. Stone (Harvard University)H-Index: 76
view all 10 authors...
Objectives To evaluate the efficacy of rituximab (RTX) in IgG4-related disease (IgG4-RD) in an open-label pilot trial. Methods We treated 30 IgG4-RD patients with two doses of RTX (1000 mg each). The participants were either treated with RTX alone (n = 26; 87%) or required to discontinue baseline glucocorticoids (GC) within 2 months (n = 4; 13%). Disease activity was measured by the IgG4-RD Responder Index (IgG4-RD RI) and physician9s global assessment (PGA). Disease response was defined as the ...
325 CitationsSource
#1Motohisa Yamamoto (Sapporo Medical University)H-Index: 35
#2Teruhito AwakawaH-Index: 2
Last. Hiroki Takahashi (Sapporo Medical University)H-Index: 51
view all 3 authors...
A prospective open-label trial of rituximab (RTX) for IgG4-related disease (IgG4-RD) was recently described in the Annals of the Rheumatic Diseases by Carruthers et al .1 According to their results, RTX is effective as induction therapy for IgG4-RD without glucocorticoid in the short term. We agree and support their results. We have also prescribed RTX for typical cases of IgG4-RD, showing characteristics of younger age, experience of several relapses, no history of hepatitis B and, since 2011, ...
35 CitationsSource
#1Zachary S. Wallace (Harvard University)H-Index: 25
#2Hamid Mattoo (Harvard University)H-Index: 21
Last. John H. Stone (Harvard University)H-Index: 76
view all 10 authors...
Objectives We examined the utility of circulating total and IgG4+ plasmablasts as biomarkers of diagnosis and disease activity in IgG4-related disease (IgG4-RD). Materials methods We evaluated patients with active, untreated, biopsy-proven IgG4-RD affecting various organs. Flow cytometry was used to measure total plasmablast and IgG4+ plasmablast counts by gating peripheral blood for CD19lowCD38+CD20−CD27+ cells and CD19lowCD38+CD20−CD27+IgG4+ cells. Serum IgG4 concentrations were measured by ne...
278 CitationsSource
#1Loïc GuillevinH-Index: 98
#2Christian PagnouxH-Index: 35
Last. Luc MouthonH-Index: 82
view all 25 authors...
BACKGROUND The combination of cyclophosphamide and glucocorticoids leads to remission in most patients with antineutrophil cytoplasm antibody (ANCA)–associated vasculitides. However, even when patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains high. Rituximab may help to maintain remission. METHODS Patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis, or renal-limited ANCA-associated vasculitis in co...
510 CitationsSource
#1Eli M. Miloslavsky (Harvard University)H-Index: 14
#2Ulrich Specks (Mayo Clinic)H-Index: 63
Last. John H. Stone (Harvard University)H-Index: 76
view all 26 authors...
Objective. Disease relapses are frequent in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). This study was undertaken to evaluate outcomes in patients with AAV who are re-treated with rituximab (RTX) and prednisone for severe disease relapses. Methods. The Rituximab in AAV trial was a randomized, double-blind, placebo-controlled trial comparing the rates of remission induction among patients treated with RTX (n = 99) and patients treated with cyclophosphamide (CYC) followed by ...
47 CitationsSource
#1Hamid Mattoo (Harvard University)H-Index: 21
#2Vinay S. Mahajan (Harvard University)H-Index: 23
Last. Shiv Pillai (Harvard University)H-Index: 50
view all 9 authors...
Background IgG 4 -related disease (IgG 4 -RD) is a poorly understood, multiorgan, chronic inflammatory disease characterized by tumefactive lesions, storiform fibrosis, obliterative phlebitis, and accumulation of IgG 4 -expressing plasma cells at disease sites. Objective The role of B cells and IgG 4 antibodies in IgG 4 -RD pathogenesis is not well defined. We evaluated patients with IgG 4 -RD for activated B cells in both disease lesions and peripheral blood and investigated their role in disea...
205 CitationsSource
#1Filip De KeyserH-Index: 8
#2Ilse HoffmanH-Index: 30
Last. Rene WesthovensH-Index: 50
view all 5 authors...
OBJECTIVE: Our study reports the results of the MIRA (MabThera In Rheumatoid Arthritis) registry, set up to collect data about clinical usage, patient profile, and retention of rituximab (RTX) treatment in daily clinical practice in Belgium. METHODS: Patients with active rheumatoid arthritis (RA) who failed at least 1 anti-tumor necrosis factor (anti-TNF) treatment were included in our study between November 2006 and October 2011. At baseline, demographics, medication, disease history, disease a...
23 CitationsSource
Cited By3
Newest
#1Penelope A McKelvie (St. Vincent's Health System)H-Index: 21
#2Alan A. McNabH-Index: 38
Last. Vivek RathiH-Index: 1
view all 4 authors...
Purpose: To compare and contrast the clinical, radiologic, pathologic, and genetic features of patients with ocular adnexal IgG4-related disease (IgG4-RD) and patients with adult ocular adnexal xanthogranulomatous disease (XG). Methods: This retrospective review study identified patients with histological evidence of either disease from records of the pathology department of our hospital from 1996 to 2014. Clinical, imaging, and a variety of histopathologic features were collected for 23 patient...
13 CitationsSource
#1Fernando Martínez-Valle (Autonomous University of Barcelona)H-Index: 8
#2Andreu Fernández-Codina (Autonomous University of Barcelona)H-Index: 9
Last. Miquel Vilardell-Tarrés (Autonomous University of Barcelona)H-Index: 37
view all 5 authors...
Abstract IgG4-related disease (IgG4-RD) is a rare autoimmune fibrosing disorder. In this review we aim to describe and compare the characteristics of the six largest IgG4-RD cohorts, since the new 2012 consensus diagnostic criteria were released. These observational studies were published between 2012 and 2015. Patients were included using the comprehensive diagnostic criteria or the 2012 consensus criteria. Results were reviewed and summarized. Most patients were middle aged men. Fibro-inflamma...
29 CitationsSource
#1Guillermo Delgado-García (Universidad Autónoma de Nuevo León)H-Index: 6
#2Sergio Sanchez-Salazar (Universidad Autónoma de Nuevo León)H-Index: 1
Last. Dionicio Ángel Galarza-Delgado (Universidad Autónoma de Nuevo León)H-Index: 10
view all 9 authors...
Coronary involvement in IgG4-related disease (IgG4-RD) has been scarcely reported, and myocardial ischemia as its presenting feature is even rarer. Here, we describe an additional case with novel and relevant observations. The patient was a previously healthy, middle-aged woman who presented to the clinic with new-onset typical angina. One tumefactive lesion encasing the left anterior descending artery was found during her workup. The most common underlying malignancies with secondary cardiac in...
10 CitationsSource